(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) rose by a staggering 34.02% in 21 sessions from $17 at 2023-01-04, to $22.79 at 13:43 EST on Friday, after three sequential sessions in a row of gains. NASDAQ is falling 0.97% to $12,082.07, after three sequential sessions in a row of gains.

Arcturus Therapeutics’s last close was $22.91, 27.06% below its 52-week high of $31.41.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Earnings Per Share

As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.48%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 11.7% and a drop 21.1% for the next.


Today’s last reported volume for Arcturus Therapeutics is 141220 which is 71.49% below its average volume of 494575.

More news about Arcturus Therapeutics (ARCT).